Reversal of DOACs: Making critical advancements
In this episode of Lab Medicine Rounds, Dr. Meera Sridharan, Assistant Professor of Medicine and Oncology and senior associate consultant in the Department of Hematology at Mayo Clinic, discusses the evolving field of direct oral anticoagulant (DOAC) reve
Lab Medicine Rounds · Mayo Clinic Laboratories
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Timestamps:
00:00 Intro
00:43 Why is it important for physicians to understand about the reversal of these direct oral anticoagulants?
03:09 The complications or the bleed rate was a lot less, with these direct oral anticoagulants?
03:57 Although there is less severe bleeding, there was a concern by patients and physicians about, if it is severe, what is the plan?
04:51 What have we learned new? Are we learning more about what patient population to use them in, as well as the plans to reverse them?
06:10 Can you elaborate a little bit about the idea for weekly monitoring for INR, why is it a big deal?
7:44 Could you give us an example of where it wouldn’t be ideal to do home INR monitoring for a given patient?
09:06 Are there updates to what the reversal plans are, and how have they changed recently?
12:34 Are there still some challenges that remain for reversing these direct oral anticoagulants?
19:54 What do you think the future looks like for anticoagulant reversal?
23:47 Outro
Resources: